Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA Negotiations: REMS Mud-Slinging, Supply Chain Compromising, GAIN Diminishing?

Executive Summary

PhRMA and GPhA exchange unpleasantries over the legislative pay-for; FDA offers a compromise track-and-trace program that would use the industry proposal as a starting point; structure of antibiotic incentives still unresolved.

You may also be interested in...



Shkreli Fallout Continues: PhRMA Seems To Soften Stance On REMS Legislation

Brand drug representative tells Senate subcommittee there are problems with bill that would make it easier for generics to obtain samples, but did not appear interested in scrapping it.

REMS Abuse Legislation: GPhA and PhRMA Set To Battle Again

Senate bill would allow generic companies to bring civil suits against brand sponsors that use REMS requirements to avoid providing samples for testing.

Should Patents On REMS Distribution Restrictions Be Banned?

Citing the use of Risk Evaluation and Mitigation Strategies to delay generic entry, Boston researchers urge Congress to revisit an “unintended consequence” created by the 2007 FDA Amendments Act.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054530

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel